Use of levetiracetam in neonatal seizures

Lloreda-García, José María; Fernández-Fructuoso, Jose Ramón; Santos, Elisabet Gómez; García-González, Ana; Leante-Castellanos, José Luis

doi:10.1016/j.anpede.2016.08.005

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than 10 published reports (mostly retrospective but at least three prospective) suggested that LEV has modest efficacy against neonatal seizures. [36][37][38][39][40][41][42][43][44][45][46][47][48] Additionally, LEV was noted to spare neuronal apoptosis in animal studies contrary to PHB. The efficacy of LEV was reported to be 30 to 84% from uncontrolled case series, primarily in retrospective studies.…”

Section: First-and Second-line Therapy and Relevant Studiesmentioning

confidence: 99%

Recent Advances in the Diagnosis and Treatment of Neonatal Seizures

Samanta

2020

Neuropediatrics

View full text Add to dashboard Cite

Seizures are the most common neurological emergency in the neonates, and this age group has the highest incidence of seizures compared with any other period of life. The author provides a narrative review of recent advances in the genetics of neonatal epilepsies, new neonatal seizure classification system, diagnostics, and treatment of neonatal seizures based on a comprehensive literature review (MEDLINE using PubMED and OvidSP vendors with appropriate keywords to incorporate recent evidence), personal practice, and experience. Knowledge regarding various systemic and postzygotic genetic mutations responsible for neonatal epilepsy has been exploded in recent times, as well as better delineation of clinical phenotypes associated with rare neonatal epilepsies. An International League Against Epilepsy task force on neonatal seizure has proposed a new neonatal seizure classification system and also evaluated the specificity of semiological features related to particular etiology. Although continuous video electroencephalogram (EEG) is the gold standard for monitoring neonatal seizures, amplitude-integrated EEGs have gained significant popularity in resource-limited settings. There is tremendous progress in the automated seizure detection algorithm, including the availability of a fully convolutional neural network using artificial machine learning (deep learning). There is a substantial need for ongoing research and clinical trials to understand optimal medication selection (first line, second line, and third line) for neonatal seizures, treatment duration of antiepileptic drugs after cessation of seizures, and strategies to improve neuromorbidities such as cerebral palsy, epilepsy, and developmental impairments. Although in recent times, levetiracetam use has been significantly increased for neonatal seizures, a multicenter, randomized, blinded, controlled phase IIb trial confirmed the superiority of phenobarbital over levetiracetam in the acute suppression of neonatal seizures. While there is no single best choice available for the management of neonatal seizures, institutional guidelines should be formed based on a consensus of local experts to mitigate wide variability in the treatment and to facilitate early diagnosis and treatment.

show abstract